MarketPeel
Insider Trading Intelligence
MW

Martin Wilson

RCKT
GENERAL COUNSEL · ROCKET PHARMACEUTICALS, INC. · CIK 0001704342
FILING MIX · LIFETIME43%/57%
BUYS
16
SELLS
21
TOTAL VALUE
$435.4K
COMPANIES
1
ACTIVE SINCE
Dec 2021
HOLDINGS NOW
677,977
AVG SELL PX
$8.94
TRADE KIND
SHOWING 37 / 37
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
14 backtested trades · 8 horizons · 19 pending
Forward-return performance of every backtestable P/S trade by Martin Wilson, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d14+50.00%+1.22%+0.33%+0.89%+1.09%
14d14+42.86%-1.25%+0.46%-1.71%+0.46%
30d14+50.00%-5.26%+0.83%-6.09%-5.86%
60d14+57.14%-8.23%+2.41%-10.64%-13.59%
90d14+64.29%-16.89%+5.19%-22.08%-22.16%
180d14(2 pending)+66.67%-27.10%+9.23%-36.33%-46.49%
1y14(6 pending)+100.00%-66.56%+18.77%-85.33%-86.12%
2y14(11 pending)+100.00%-85.79%+39.33%-125.12%-127.56%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
RCKT · 677,977 shares · as of May 19, 2026
0173,907347,815521,722695,62920222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 16 buys / 21 sellsCOVERAGE · 19 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
RCKT
ROCKET PHARMACEUTICALS, INC.
SALE
General Counsel
662$3.01$2.0K677,977May 19, 2026May 21, 2026View →
RCKT
ROCKET PHARMACEUTICALS, INC.
SALE
General Counsel
3,361$3.61$12.1K678,639May 13, 2026May 14, 2026View →
RCKT
ROCKET PHARMACEUTICALS, INC.
SALE
General Counsel
1,376$3.34$4.6K682,000Feb 18, 2026Feb 20, 2026View →
RCKT
ROCKET PHARMACEUTICALS, INC.
SALE
General Counsel
12,253$3.31$40.6K683,376Feb 13, 2026Feb 18, 2026View →
RCKT
ROCKET PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
468,187468,187Feb 11, 2026Feb 13, 2026View →
RCKT
ROCKET PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
311,813695,629Feb 11, 2026Feb 13, 2026View →
RCKT
ROCKET PHARMACEUTICALS, INC.
SALE
General Counsel
1,646$2.98$4.9K383,816Nov 18, 2025Nov 20, 2025View →
RCKT
ROCKET PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
100,000385,462Nov 3, 2025Nov 10, 2025View →
RCKT
ROCKET PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
150,000285,462Sep 8, 2025Sep 9, 2025View →
RCKT
ROCKET PHARMACEUTICALS, INC.
SALE
General Counsel
588$3.00$1.8K135,462Aug 19, 2025Aug 20, 2025View →
RCKT
ROCKET PHARMACEUTICALS, INC.
SALE
General Counsel
1,004$3.07$3.1K136,050Aug 18, 2025Aug 20, 2025View →
RCKT
ROCKET PHARMACEUTICALS, INC.
SALE
General Counsel
12,109$3.02$36.6K137,054Aug 14, 2025Aug 18, 2025View →
RCKT
ROCKET PHARMACEUTICALS, INC.
SALE
General Counsel
587$6.45$3.8K149,163May 20, 2025May 22, 2025View →
RCKT
ROCKET PHARMACEUTICALS, INC.
SALE
General Counsel
946$6.53$6.2K149,750May 16, 2025May 20, 2025View →
RCKT
ROCKET PHARMACEUTICALS, INC.
SALE
General Counsel
3,222$10.58$34.1K150,696Feb 21, 2025Feb 25, 2025View →
RCKT
ROCKET PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
90,358153,918Feb 11, 2025Feb 13, 2025View →
RCKT
ROCKET PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
134,642134,642Feb 11, 2025Feb 13, 2025View →
RCKT
ROCKET PHARMACEUTICALS, INC.
SALE
General Counsel
1,175$13.05$15.3K63,560Nov 21, 2024Nov 25, 2024View →
RCKT
ROCKET PHARMACEUTICALS, INC.
SALE
General Counsel
1,027$18.50$19.0K64,735Aug 16, 2024Aug 20, 2024View →
RCKT
ROCKET PHARMACEUTICALS, INC.
SALE
General Counsel
1,048$23.35$24.5K65,762May 16, 2024May 20, 2024View →
RCKT
ROCKET PHARMACEUTICALS, INC.
SALE
General Counsel
2,42016,947May 14, 2024May 20, 2024View →
RCKT
ROCKET PHARMACEUTICALS, INC.
PURCHASE
General Counsel
2,42021,100May 14, 2024May 20, 2024View →
RCKT
ROCKET PHARMACEUTICALS, INC.
SALE
General Counsel
4,100$29.33$120.3K18,680Feb 29, 2024Mar 4, 2024View →
RCKT
ROCKET PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
16,64422,780Feb 16, 2024Feb 21, 2024View →
RCKT
ROCKET PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
49,09149,091Feb 16, 2024Feb 21, 2024View →
RCKT
ROCKET PHARMACEUTICALS, INC.
SALE
General Counsel
3,576$29.84$106.7K6,136Feb 16, 2024Feb 21, 2024View →
RCKT
ROCKET PHARMACEUTICALS, INC.
SALE
General Counsel
9,7129,712Feb 14, 2024Feb 16, 2024View →
RCKT
ROCKET PHARMACEUTICALS, INC.
SALE
General Counsel
9,71219,367Feb 14, 2024Feb 16, 2024View →
RCKT
ROCKET PHARMACEUTICALS, INC.
PURCHASE
General Counsel
16,94766,810Feb 14, 2023May 20, 2024View →
RCKT
ROCKET PHARMACEUTICALS, INC.
SALE
General Counsel
16,9470Feb 14, 2023May 20, 2024View →
RCKT
ROCKET PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
87,14787,147Feb 14, 2023Feb 16, 2023View →
RCKT
ROCKET PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
29,07929,079Feb 14, 2023Feb 16, 2023View →
RCKT
ROCKET PHARMACEUTICALS, INC.
PURCHASE
General Counsel
28,76349,863Aug 12, 2022May 20, 2024View →
RCKT
ROCKET PHARMACEUTICALS, INC.
SALE
General Counsel
28,7630Aug 12, 2022May 20, 2024View →
RCKT
ROCKET PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
28,76328,763Aug 12, 2022Aug 16, 2022View →
RCKT
ROCKET PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
20,31820,318Aug 12, 2022Aug 16, 2022View →
RCKT
ROCKET PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
100,000100,000Dec 6, 2021Dec 8, 2021View →
Other insiders · RCKT
Loading peer insiders…
About this filer
CIK 0001704342
ROLE
General Counsel
PRIMARY
RCKT
COMPANIES
1
ACTIVE SINCE
Dec 2021
MARKETPEEL · /INSIDER/0001704342DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback